Benjamin Derman

Benjamin Derman is an Assistant Professor at the University of Chicago in the Department of Medicine-Hematology and Oncology. His work focuses on multiple myeloma, immunotherapy, and clinical trials for hematologic malignancies.

• Key Research Areas: Hematology, Oncology, CAR T-cell therapy, Measurable Residual Disease (MRD), Plasma cell dyscrasias
• Clinical Trials: Active investigator in trials involving daratumumab, carfilzomib, teclistamab, and BCMA CAR T-cell therapy

His recent publications emphasize CAR T-cell therapy optimization (e.g., Blood Adv 2025), real-world evidence in myeloma treatment (e.g., Cancers 2025), and MRD-guided treatment cessation (e.g., Lancet Haematol 2023). Collaborations with Andrzej Jakubowiak, Jennifer Cooperrider, and Satyajit Kosuri highlight his role in clinical and translational research.